<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087672</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0648</org_study_id>
    <nct_id>NCT00087672</nct_id>
  </id_info>
  <brief_title>A Phase II Study of CC-5013 in Myelofibrosis</brief_title>
  <official_title>Phase II Study of CC-5013 in Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to
      control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also
      be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lenalidomide blocks the activity of a substance in the blood called tumor necrosis factor
      alpha. Tumor necrosis factor alpha is a substance that is believed to prevent new blood cells
      from forming in the bone marrow. Lenalidomide is also believed to help the body's immune
      system fight diseases.

      Before treatment starts, you will have a complete physical exam, including blood (about 3
      teaspoonfuls) and urine tests. A bone marrow sample will be taken. To collect a bone marrow
      sample, an area of the hip or chest bone is numbed with anesthetic and a small amount of bone
      marrow is withdrawn through a large needle. An ECG (test to measure the electrical activity
      of the heart) may be performed.

      Women who are able to have children must have a negative pregnancy test [blood (about 1
      teaspoon) or urine]. These pregnancy tests must occur within 10 - 14 days and again within 24
      hours before the start of lenalidomide. Women who are able to have children with regular or
      no menstruation must have a pregnancy test weekly for the first 28 days and then every 28
      days while on therapy (including breaks in therapy); when they stop taking lenalidomide and
      at Day 28 after the last dose of lenalidomide. Females with irregular menstruation must have
      a pregnancy test weekly for the first 28 days and then every 14 days while on therapy
      (including breaks in therapy), when they stop taking lenalidomide and at Day 14 and Day 28
      after the last dose of lenalidomide.

      You are considered to be a woman who is able to have children if you are a sexually mature
      female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
      naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time
      in the preceding 24 consecutive months).

      You will take 2 lenalidomide capsules by mouth daily. You should swallow lenalidomide
      capsules whole with water at the same time each day. Do not break, chew or open the capsules.
      If you miss a dose of lenalidomide, take it as soon as you remember on the same day. If you
      miss taking your dose for the entire day, take your regular dose the next scheduled day (do
      NOT take double your regular dose to make up for the missed dose).

      If your platelet count is less than 100,000 at the time of study enrollment, the dose will be
      one capsule daily. The dose may be decreased depending on side effects. The dose may be
      increased if needed to better control the disease. This will be decided cycle by cycle.

      During treatment, you will give blood samples (about 1 tablespoon each) about every week. The
      tests may be repeated more frequently to check for side effects. You will need to return to
      M. D. Anderson monthly for the first 3 months, then at least every 3 months afterwards (while
      on the study) in order to be evaluated for response and tolerance to lenalidomide. Only one
      28-day cycle of lenalidomide may be given to you for each cycle per month.

      You may continue to receive this therapy as long as there are no severe side effects or
      worsening of the disease. You will be asked to keep diaries documenting when you take the
      capsules. You will also need to return empty medication bottles at each visit. If you have
      had 4 to 6 months of treatment without any evidence of benefit, you may be taken off the
      study.

      This is an investigational study. Lenalidomide is a new drug related to the drug called
      thalidomide. Lenalidomide is approved by the Food and Drug Administration (FDA) for the
      treatment of specific types of myelodysplastic syndrome (MDS) and in combination with
      dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior
      therapy. MDS and MM are cancers of the blood. It is currently being tested in a variety of
      cancer conditions. In this case it is considered investigational. Up to 41 participants may
      take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of CC-5013 in Myelofibrosis</measure>
    <time_frame>3 - 4 Months for all patients; 24 months for responders</time_frame>
    <description>Response evaluation, sustained for 2 weeks: Complete Remission (Neutrophil count between 1 to 10 x 10^9/L without peripheral blasts in blood or bone marrow); Partial Hematologic Response/Partial Remission (Increase in neutrophil by 50% + above 10^9/L for neutropenia); Hematologic Improvement (increase in Neutrophil count, hemoglobin, platelet count or reduction in blood/marrow blasts) or No Response.
If nine or &lt; patients respond to therapy (response other than 'No Response'), therapy declared ineffective. However, if 11 or &gt; patients respond to therapy, therapy considered efficacious.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>CC-5013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-5013</intervention_name>
    <description>10 mg orally (2 capsules) daily</description>
    <arm_group_label>CC-5013</arm_group_label>
    <other_name>lenalidomide</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of myelofibrosis or Philadelphia negative myeloproliferative disorder with
             myelofibrosis requiring therapy.

          -  Disease-free of prior malignancies for greater than or equal to 2 years with exception
             of basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the
             cervix or breast.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.

          -  Total bilirubin less than or equal to 3.0 mg/dL (unless due to tumor) and serum
             creatinine less than or equal to 3.0 mg/dL (unless due to tumor).

          -  Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of starting lenalidomide and must either commit to continued
             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
             control, one highly effective method and one additional effective method AT THE SAME
             TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to
             ongoing pregnancy testing.

          -  continued from above.....Men must agree to use a condom during sexual contact with a
             female of child bearing potential even if they have had a successful vasectomy. All
             patients must be counseled at a minimum of every 28 days about pregnancy precautions
             and risks of fetal exposure.

          -  continued from above.....† A female of childbearing potential is a sexually mature
             woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has
             not been naturally postmenopausal for at least 24 consecutive months (i.e., has had
             menses at any time in the preceding 24 consecutive months).

          -  Signed informed consent.

        Exclusion Criteria:

          -  Use of any other experimental drug or therapy within 28 days of therapy, except in
             cases with rapidly progressive disease and/or recovery from all toxicity from previous
             therapy (does not apply to growth factors).

          -  Platelet count less than 30,000.

          -  Known prior clinically relevant hypersensitivity reaction or desquamating rash with
             thalidomide.

          -  Prior therapy with CC-5013.

          -  Pregnancy, suspected pregnancy or breast feeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge E Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Website for The University of Texas M.D. Anderson Cancer Center</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2004</study_first_submitted>
  <study_first_submitted_qc>July 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2004</study_first_posted>
  <results_first_submitted>September 15, 2009</results_first_submitted>
  <results_first_submitted_qc>January 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Philadelphia negative myeloproliferative disorder</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Antiangiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 7/8/04 to 2/27/09. All patients registered at the University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>The maximum accrual of 41 was met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CC-5013</title>
          <description>10 mg orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CC-5013</title>
          <description>10 mg orally daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of CC-5013 in Myelofibrosis</title>
        <description>Response evaluation, sustained for 2 weeks: Complete Remission (Neutrophil count between 1 to 10 x 10^9/L without peripheral blasts in blood or bone marrow); Partial Hematologic Response/Partial Remission (Increase in neutrophil by 50% + above 10^9/L for neutropenia); Hematologic Improvement (increase in Neutrophil count, hemoglobin, platelet count or reduction in blood/marrow blasts) or No Response.
If nine or &lt; patients respond to therapy (response other than 'No Response'), therapy declared ineffective. However, if 11 or &gt; patients respond to therapy, therapy considered efficacious.</description>
        <time_frame>3 - 4 Months for all patients; 24 months for responders</time_frame>
        <population>Intention to treat: After a total of 41 patients were enrolled in study, nine or more patients responded to the therapy, therapy declared effective.</population>
        <group_list>
          <group group_id="O1">
            <title>CC-5013</title>
            <description>10 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of CC-5013 in Myelofibrosis</title>
          <description>Response evaluation, sustained for 2 weeks: Complete Remission (Neutrophil count between 1 to 10 x 10^9/L without peripheral blasts in blood or bone marrow); Partial Hematologic Response/Partial Remission (Increase in neutrophil by 50% + above 10^9/L for neutropenia); Hematologic Improvement (increase in Neutrophil count, hemoglobin, platelet count or reduction in blood/marrow blasts) or No Response.
If nine or &lt; patients respond to therapy (response other than 'No Response'), therapy declared ineffective. However, if 11 or &gt; patients respond to therapy, therapy considered efficacious.</description>
          <population>Intention to treat: After a total of 41 patients were enrolled in study, nine or more patients responded to the therapy, therapy declared effective.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CC-5013</title>
          <description>10 mg orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Obstruction Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Unrelated to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection with neutropenia</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection with unknown Absolute neutrophil count</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope, sensory neuropathy</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <description>Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory (other)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain (headache)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutrophils (ANC/AGC)</sub_title>
                <description>ANC/AGC = Absolute Neutrophil Count/Absolute Granulocyte Count</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle cramps</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy Sensory</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Cortes, M.D./ Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713-794-5783</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

